High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.
about
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.CD4 is a critical component of the receptor for human herpesvirus 7: interference with human immunodeficiency virusIn vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivityPathogenesis of human immunodeficiency virus infectionHIV-1 entry inhibitors: an overviewTemporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndromeHIV-1 neutralizing antibodies: understanding nature's pathwaysHIV-1 entry inhibitors: recent development and clinical useAdditive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibitionIn vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinationsInhibition of human immunodeficiency virus type 1 transcription and replication by DNA sequence-selective plant lignansInfection by HIV-1 blocked by binding of dextrin 2-sulphate to the cell surface of activated human peripheral blood mononuclear cells and cultured T-cellsPeptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infectionTriterpene derivatives that block entry of human immunodeficiency virus type 1 into cellsAnti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactionsTwo HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entryA novel small-molecule inhibitor of HIV-1 entryInduction of a Tier-1-like Phenotype in Diverse Tier-2 Isolates by Agents that Guide HIV-1 Env to Perturbation-sensitive, Non-native States.Nef does not contribute to replication differences between R5 pre-AIDS and AIDS HIV-1 clones from patient ACH142Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cellsSimple assay to screen for inhibitors of interaction between the human immunodeficiency virus envelope glycoprotein and its cellular receptor, CD4Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor.Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state.Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kineticsLiposome-mediated delivery of antiviral agents to human immunodeficiency virus-infected cells.Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4.Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines.Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope.A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor.Soluble forms of the subgroup A avian leukosis virus [ALV(A)] receptor Tva significantly inhibit ALV(A) infection in vitro and in vivo.Characterization of primary isolate-like variants of simian-human immunodeficiency virusImproved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelopeEnvelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys.Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropismVirus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates
P2860
Q24531479-E0DB3B87-80D5-4513-83AE-2442BC090537Q24563446-A9A9FEDF-DDEB-43AA-9686-C3092C458447Q24563455-7000981A-8D72-4D9F-A70C-9FF5CC8B1083Q24634681-C2CFA0CC-F33E-479B-96AE-53748EF3E012Q24645525-B464D8C1-53D5-469A-8C57-4F7360E58479Q24648628-40A53436-60E4-4E0B-8786-8D2A322E8CF5Q27000480-3AFA35F7-99FB-43B4-B0F6-EA0332A06CB1Q27003887-8BB3949D-9C80-4309-9064-5B0D26E405DBQ27469855-23FCB24A-14E7-43C8-9213-C216ECCAFD31Q28317348-436F8214-4F76-44A9-A787-E998135097EFQ28318476-087B3B6D-1B43-44FC-A4F5-FFDA6C0AE719Q28367369-B7278F80-A584-4E0C-94FD-80EB3E3449ABQ28368254-ACC219B1-E6D2-48A9-9931-C5184E20D740Q28369033-C3813891-E064-430D-9EF0-9AB3C6C78CDEQ28369657-B31C7405-7911-4075-8BD0-6C460D18DA34Q28378840-785ED79A-CF56-43BB-A267-03907D1C09C4Q28475912-4A6B9544-42AB-496F-A453-3EADB8C5157AQ28606625-439A4DDE-04CC-43D9-B3B8-FDA63661A1FEQ30401836-FF95EC28-0227-4525-8E38-3B471AD8D5F1Q30441489-C38EC727-7CB5-4EA1-BEA1-273B7369E56AQ30859838-91A228ED-0BE9-4D9C-8292-A9E2E55CF565Q33220705-D5250FA7-1249-4AC5-8231-020D4D7883DFQ33223969-1D824362-B183-4DC6-93C0-8F78CCE7BB4CQ33426352-1D6A11C4-B5AC-43AF-8A21-00C2F03BB7BAQ33429049-C970065B-BE18-4B42-9C4F-750EBB0C3464Q33637970-991A77F2-E609-4370-8492-084017E9B7D8Q33780620-74D2D0A3-F813-4612-8514-A1C135B59034Q33782007-51837AD9-0157-41C2-BBC2-A0F0A418F93AQ33788810-3FF37288-9465-4DBB-AD74-08F3B957C127Q33813526-9B23EA6F-A34F-46B8-A6B3-63EE19CF548EQ33822395-9788512F-AFA1-4194-B7A1-63D9C698C75DQ33825013-D21F3698-7E70-457F-B55E-69AADDAB4E5DQ33825229-C988A1C6-2FE4-40A5-83A1-B8275DDE1DEAQ33836042-C9327D64-63CE-49F3-B0EC-5473B274F745Q33839402-769CFB3E-C2CF-4CED-892F-76749767F740Q33839485-ACFE60C5-981F-4A94-BE6C-44051FADC1F2Q33842286-8AD594C1-2D6B-4FE8-85C6-4ADE9E3E5267Q33842455-ABA01B9E-3A8B-4B76-97A8-2B36C2D3118DQ33843345-205F6454-B038-4F57-835E-EA0C2963AD9BQ33844079-0231C24C-9C9C-4DE2-97CA-7BEF218DBEAB
P2860
High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.
description
1990 nî lūn-bûn
@nan
1990 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
High concentrations of recombi ...... iciency virus type 1 isolates.
@ast
High concentrations of recombi ...... iciency virus type 1 isolates.
@en
type
label
High concentrations of recombi ...... iciency virus type 1 isolates.
@ast
High concentrations of recombi ...... iciency virus type 1 isolates.
@en
prefLabel
High concentrations of recombi ...... iciency virus type 1 isolates.
@ast
High concentrations of recombi ...... iciency virus type 1 isolates.
@en
P2093
P2860
P356
P1476
High concentrations of recombi ...... iciency virus type 1 isolates.
@en
P2093
P2860
P304
P356
10.1073/PNAS.87.17.6574
P407
P577
1990-09-01T00:00:00Z